What Happened?
New Haven, Connecticut-based Arvinas Appointed Justin Scheidegger as Director, IT Operations, Infrastructure and Security
About the Company
Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.
About the Person
Justin Scheidegger is Director, IT Operations, Infrastructure and Security at Arvinas. Previously, Justin held various senior IT leadership roles in the industry.
Info Source
News
Short Profile